{"url_path":"/sec/amix/8-k/2026-06-24/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1617867/0001437749-26-021495-index.html","accession_number":"0001437749-26-021495","cik":"0001617867","ticker":"AMIX","issuer_name":"Autonomix Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1617867/0001437749-26-021495-index.html","primary_entity_key":"0001617867","primary_entity_name":"Autonomix Medical, Inc."},"word_count":238,"has_tables":true,"body_markdown":"**Item 8.01. Other Events**\n\n \n\nOn June 18, 2026, the Company issued a press release to announce that it filed a certificate of amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21 reverse stock split of its common stock. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.\n\n \n\nThe table below sets forth the impact of the Reverse Stock Split on the Company’s net loss per common share – basic and diluted, and weighted average common shares outstanding – basic and diluted for the years ended March 31, 2026 and 2025, prior to any final adjustments required by the Depository Trust & Clearing Corporation or the Company's Transfer Agent. Theweighted average common sharesoutstanding and net loss per common share amounts for all periods presented have been retroactively adjusted to reflect the reverse stock split as if it occurred at the beginning of the earliest period presented.\n\n \n\n \n \n\n**Dollars in thousands, except share and per share data**\n\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \n\n**Pre-Split**\n\n \n \n\n**Post-Split**\n\n \n\n \n \n\n**Year ended March 31,**\n\n \n \n\n**Year ended March 31,**\n\n \n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n \n\n**2026**\n\n \n \n\n**2025**\n\n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nNet Loss\n\n \n$\n(16,715\n)\n \n$\n(11,410\n)\n \n$\n(16,715\n)\n \n$\n(11,410\n)\n\nNet loss per common share – basic and diluted\n\n \n$\n(2.32\n)\n \n$\n(6.46\n)\n \n$\n(48.80\n)\n \n$\n(137.44\n)\n\nWeighted average common shares outstanding – basic and diluted\n\n \n \n7,216,757\n \n \n \n1,766,425\n \n \n \n342,539\n \n \n \n83,020"}